FindTrial
Sign In

Cell subsets in blood as a biomarker for Bronchiolitis Obliterans Syndrome (BOS)

Cell subsets in blood as a biomarker for Bronchiolitis Obliterans Syndrome (BOS) - subsets BOS

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON45481
Enrollment
30
Registered
2017-03-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Afstoting na long transplantatie "Bronchiolitis Obliterans Syndrome (BOS)" "Chronische afstoting na Longtransplantatie"

Interventions

Biomarker
Bronchiolitis Obliterans Syndrome
Lungtransplantation
Subsets

Sponsors

Sint Antonius Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Patients that underwent a lung transplantation and are receiving follow-up care at the St. Antonius Hosptital. At this point in time there are 10 BOS diagnosed patients receiving follow-up care at the St. Antonius Hosptial. Next to these 10, we want to include 20 lung transplantation patients without BOS. 20 healthy controls will be acquired through corporations like Sanquin.

Exclusion criteria

Exclusion criteria: 1. Not willing to participate 2. Acute rejection after transplantation

Design outcomes

Primary

MeasureTime frame
1. Difference in immune-cell subset composition in peripheral blood, between patients and controls 2. Activation marker expression 2. Cytokine production capacity 3. Differentiation directional—

Secondary

MeasureTime frame
1. Sex 2. Age 3. Time between tranplantation and BOS diagnosis 4. Medication—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)